Publisher
Springer Nature Switzerland
Reference53 articles.
1. Jiang, Y., Chen, M., Nie, H., Yuan, Y.: PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum. Vaccin. Immunother. 15(5), 1111–1122 (2019)
2. Han, Y., Liu, D., Li, L.: PD-1/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res. 10(3), 727–742 (2020)
3. Ishida, Y., Agata, Y., Shibahara, K., Honjo, T.: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11(11), 3887–3895 (1992)
4. Pascolutti, R., Sun, X., Kao, J., Maute, R., Ring, A.M., Bowman, G.R., et al.: Structure and dynamics of PD-L1 and an ultra high-affinity PD-1 receptor mutant. Structure 24(10), 1719–1728 (2016)
5. Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H., et al.: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8(5), 765–772 (1996)